Emergent BioSolutions gets $100 million anthrax contract from feds

Gaithersburg-based Emergent BioSolutions Inc. won another lucrative anthrax contract from the feds, this time totaling $100 million over two years. Emergent (NYSE: EBS) received the contract through the Biomedical Advanced Research and Development Authority to add more of its anthrax vaccine, BioThrax, to the country's national stockpile. The company first announced the planned purchase in December, along with another Centers for Disease Cont rol and Prevention contract worth up to $911 million for…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news